Mechanisms of Immune Evasion in Chronic Hepatitis B Infection: The Role of Cytokines and Immune Cells
Main Article Content
Abstract
Background: Chronic hepatitis B (CHB) affects approximately 296 million people globally, causing significant liver fibrosis and cancer. CHB is characterized by immune dysfunction, including impaired innate responses, defective intercellular signaling, and exhausted T/NK cells regulated via PD-1/PD-L1 checkpoints. The precise link between cytokine dysregulation and cellular exhaustion within the human liver remains poorly understood. Objective: To investigate CHB immune evasion mechanisms through computational analysis of published human liver datasets, examining relationships between immune recognition, antigen presentation, checkpoint pathway activation, and cytokine environments including IL-10, TGF-β, and IFN-α/γ in shaping T/NK cell functional states across disease progression. Methods: Liver biopsy data from CHB patients across three datasets (GSE84044, GSE83898, GSE230397; n=120) underwent normalization and immune deconvolution using CIBERSORTx and EPIC. Differential expression, gene set enrichment, checkpoint interactions, and cytokine signaling were quantified alongside known HBV immune evasion mechanisms including RIG-I/MDA5 inhibition and HBsAg/HBeAg-mediated suppression. Results: CHB livers showed attenuated antiviral responses with reduced ISG expression, elevated IL-10/TGF-β, and altered Kupffer/monocyte phenotypes. Enhanced PD-L1 on liver and myeloid cells interacted with exhausted T/NK populations via PD-1, LAG-3, and CD94, with reduced cytotoxic CD8+ effectors and expansion of tolerogenic Tregs. HBx and polymerase-mediated PD-L1 upregulation were identified as central dysfunction drivers. Conclusions: CHB immune escape involves a self-reinforcing cycle where viral antigens suppress immunosurveillance and promote IL-10/TGF-β-dominated immunopathology, sustaining T/NK exhaustion. Biomarkers including PD-L1, IL10/TGFB1 modules, and the CD94/HLA-E axis may stratify patients and guide combination immunotherapies targeting checkpoint blockade alongside cytokine pathway modulation.
Article Details
Section
How to Cite
References
1. Fisicaro P. et al., “Pathogenic Mechanisms of HBV-Specific T Cell Dysfunction,” Gastroenterology, vol. 153, no. 6, pp. 1676–1690, 2017.
2. Das A. et al., “Transcriptomic Landscape of HBV Immune Tolerance,” J Hepatol, vol. 68, no. 5, pp. 1037–1045, 2018.
3. Bertoletti A. and Ferrari C., “Adaptive Immunity in Chronic Hepatitis B,” Semin Liver Dis, vol. 38, no. 3, pp. 230–241, 2018.
4. Revill P. et al., “The Global HBV Cure Agenda,” Nat Rev Gastroenterol Hepatol, vol. 17, pp. 618–629, 2020.
5. Dandri M., “Immunopathogenesis of HBV Infection,” Semin Liver Dis, vol. 40, no. 4, pp. 345–359, 2020.
6. Xu L. et al., “Cytokine Networks in Viral Hepatitis,” Cell Reports, vol. 35, no. 5, pp. 109–121, 2021.
7. Rehermann B., “Immune Control and Immune Evasion in HBV Infection,” Semin Liver Dis, vol. 41, no. 1, pp. 10–23, 2021.
8. Wang S. et al., “PD-L1 Expression Correlates with Viral Antigen Load in HBV,” Cell Reports Medicine, vol. 2, no. 6, pp. 100–115, 2021.
9. Maini M.K. and Gehring A.J., “The Role of T Cells in HBV Persistence,” Nat Rev Immunol, vol. 22, no. 5, pp. 307–320, 2022.
10. Kim Y.J. et al., “The Balance between Tolerance and Immunity in HBV,” Immunity, vol. 55, no. 3, pp. 545–559, 2022.
11. Su T.H. et al., “Clinical and Immunological Profiles of CHB Patients Under Antiviral Therapy,” J Clin Invest, vol. 132, no. 12, 2022.
12. Wang H. et al., “HBV-specific T Cell Exhaustion and Its Reversal,” J Hepatol, vol. 78, no. 3, pp. 495–510, 2023.
13. Lu M. et al., “Integrated Multi-Omic Profiling of HBV Immune States,” Hepatology Communications, 2023.
14. Zhang Y. et al., “TGF-β Signaling Drives PD-L1 Expression in Chronic Hepatitis B,” Nat Commun, vol. 14, no. 557, 2023.
15. Pan C. et al., “Role of IL-10 and TGF-β in Modulating Liver Immunity,” Front Immunol, 2023.
16. Li W. et al., “HBV-mediated Reprogramming of Myeloid Cells,” Nat Immunol, vol. 25, pp. 77–89, 2024.
17. Li J. et al., “Dual Regulation of PD-L1 by SMAD3 and STAT3 in HBV-induced Immune Tolerance,” Hepatology, 2024.
18. Gao B. et al., “NK Cell Dysfunction in CHB is Linked to Cytokine-Mediated Checkpoint Activation,” Front Immunol, vol. 15, 2024.
19. Fisicaro P. and Ferrari C., “Therapeutic Restoration of T Cell Function in HBV,” Semin Immunopathol, 2024.
20. Li M. et al., “HBV Immune State Dynamics Revealed by Longitudinal Profiling,” J Infect Dis, 2024.
21. Wang H., “Clinical Immunotherapy Advances in HBV,” Hepatology Reports, 2024.
22. Gao J. et al., “HLA-E Mediated NK Inhibition in Chronic HBV,” Front Immunol, 2024.
23. Lin S. et al., “Cytokine-Checkpoint Synergy in HBV,” Nat Immunol, 2025.
24. Chen J. et al., “Single-Cell Characterization of Hepatic Immune Exhaustion,” Front Immunol, vol. 10, 2019.
25. Fisicaro P. et al., “HBV-specific T Cell Functional Recovery Post-Therapy,” Hepatology, vol. 80, no. 1, 2024.
26. Lu M. and Maini M.K., “Mechanisms of Immune Restoration in HBV Cure,” Nat Rev Immunol, 2025.
27. Gehring A.J. et al., “IL-10 and PD-L1 Crosstalk in Chronic Infection,” Immunity, 2025.
28. Zhou Z. et al., “Therapeutic Targeting of IL-10 Pathway in CHB,” J Hepatol, 2025.
29. Li T. et al., “Integrative Immunotherapy Approaches in HBV,” Nat Biomed Eng, 2025.
30. Maini M.K., “Reprogramming Tolerance in Chronic HBV,” Cell Reports Medicine, 2025.
31. Zhang L. et al., “Combinatorial Cytokine and Checkpoint Inhibition Restores HBV Immunity,” Nat Med, 2025.
32. Chen F. et al., “PD-L1/IL-10 Axis in Hepatic Immune Regulation,” Hepatology Communications, 2025.
33. Fisicaro P. et al., “IL-10-Driven Regulatory Circuits in Chronic Hepatitis B,” Front Immunol, 2025.
34. Li X. et al., “Machine Learning-Based Stratification of CHB Immune States,” Hepatology, 2025.
35. Wang H. et al., “Cytokine Blockade and Checkpoint Therapy Synergy in HBV,” Nat Commun, 2025.